

GRI Bio, Inc. (Nasdaq CM: GRI) is a company specializing in creating innovative approaches in early-phase development programs.
Nasdaq CM: GRI
IR Website: https://gribio.com/investors/
Nasdaq Profile: https://www.nasdaq.com/market-activity/stocks/gri
Headquarters: La Jolla, California
The leadership team is filled with industry experts, including CEO Marc Hertz, Ph.D., with extensive executive, operational, and R&D experience, CSO Vipin Kumar, Ph.D., an internationally renowned NKT researcher, and CMO Albert Agro, Ph.D., bringing a successful track record of 20 + years in research.
TALK TO MANAGEMENT
GRI Bio is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.
Investor Presentation

To download the GRI Bio, Inc. investor presentation, please fill out the form below.
Stock Chart (Intraday)
Stock Chart (Historical)
Stock Detail
An Exceptional and Experienced Management Team

Marc Hertz, Ph.D. - PRESIDENT, CHIEF EXECUTIVE OFFICER AND DIRECTOR
Dr. Hertz has over 20+ years of executive, operational, and R&D experience. Previously, Dr. Hertz co-founded and served as Chief Executive Officer of several other companies. He received his undergraduate biology degree from Bowdoin College and his doctoral degree from the University of Colorado Medical School.
Vipin Kumar Chaturvedi, Ph.D. - CHIEF SCIENTIFIC OFFICER
Dr. Chaturvedi co-founded GRI in 2009 and, since its inception, has served as a member of its board of directors and as Chairman of its scientific advisory board. Dr. Chaturvedi served as GRI’s Chief Scientific Officer from 2009 to 2017 and reassumed the role in 2022. Dr. Chaturvedi has served as a Professor at the University of California, San Diego, since April 2015. Dr. Chaturvedi obtained his undergraduate degree from Kanpur University, India, and his master's from the Institute of Medical Education & Research, India, and his Ph.D. in biochemistry from the Indian Institute of Science India.
Albert Agro, Ph.D. - CHIEF MEDICAL OFFICER
Dr. Agro co-founded GRI in 2009 and has served as a consultant to GRI with the title of Chief Medical Officer since August 2017. Dr. Agro has served as President and Chief Executive Officer of Columbia Therapeutics Inc. since April 2021 and has over 20 years of experience. Additionally, Dr. Agro currently serves as an assistant professor at McMaster University. Dr. Agro received a Ph.D. from McMaster University.
Leanne Kelly - CHIEF FINANCIAL OFFICER
Ms. Kelly has served as GRI Bio’s Chief Financial Officer since April 2023. She brings over 20 years of experience leading private and publicly traded companies with a foundation in public accounting. Ms. Kelly received her undergraduate degree in business economics with a concentration in accounting from Lehigh University and is a licensed CPA (inactive status) in the State of Pennsylvania.
SEC Filings
Financials
Risks & Disclosures

This communication is neither an offer to sell nor a solicitation of an offer to buy, nor a recommendation of any securities of the company mentioned herein.
GRI Bio, Inc. (the “Company”) has reviewed the content of this page as well as the accompanying presentation (“Company Presentation”) displayed on this page. To the best of its knowledge, the Company does not believe this content to be misleading or inaccurate in any material respect, nor does it believe there are any material omissions with respect to such content. The Company does not believe the contents of the page or the Company Presentation to contain any non-public material information.
Information and opinions presented in the Company Presentation are provided by the Company, and b2iDigital makes no representation as to their accuracy or completeness. The information contained on this page is not intended to constitute any form of advice, and the information provided is not intended to provide a sufficient basis on which to make an investment decision. It is not investment research, nor does it constitute a research recommendation, as it does not constitute substantive research or analysis. This information is not to be relied upon in substitution for the exercise of independent judgment.
Information, opinions and estimates contained on this page or in the Company Presentation reflect judgments by the Company as of the original date of publication by the Company and are subject to change without notice. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance.
A complete description of the risks and uncertainties relating to the Company and its securities can be found in the company's filings with the U.S. Securities and Exchange Commission available for free at www.sec.gov.
Information on this page may relate to penny stocks, which may also be referred to as low-priced stocks. Penny stocks are low-priced shares typically issued by small companies. Penny stocks involve greater than normal risk, they may be less liquid than other stocks (i.e., more difficult to sell), and there may be less reliable information available regarding such stocks. Investors in penny stocks should be prepared for the possibility that they may lose their entire investment.
b2i digital or its related entities may own securities of the Company.
The Company is a client of b2i Digital. The Company agreed to pay b2i Digital no greater than $100,000 in cash for 12 months of digital marketing consulting and investor awareness services.
This communication includes forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believes,” “hopes,” “intends,” “estimates,” “expects,” “projects,” “plans,” “anticipates” and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Company’s forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks, uncertainties and other factors. The Company urges readers to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this communion. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this communication.
SEE THE FULL IN DEPTH STORY
The GRI Bio management and investor relations team are available to talk to current and potential investors. They're happy to answer your questions and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.
• Directly hear the GRI Bio story
• Ask your questions
• Submit the form below, and someone will get in touch with you as soon as possible
Note: Company management or its representative can only discuss and disclose information that is already available in the public domain. They will do their best to clarify such information to the extent permitted by securities law and industry regulations.